EVENTS · QURE
PEERS
EARNINGS
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.
UniQure released third quarter results and said the FDA granted priority review for its Huntington's disease gene therapy, yet the shares fell despite that seemingly positive update
| Series | 1W | 1M |
|---|---|---|
| QURE | −7.6% | +0.1% |
| Peers | +1.5% | +5.2% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 13 | 25 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | −0.84 | −0.88 | −4.76% | — |
| Q2 FY2026 | −0.84 | −1.22 | −45.12% | — |
| Q1 FY2026 | −0.89 | −0.85 | +4.88% | — |
| Q4 FY2025 | −0.97 | −0.64 | +33.69% | — |
| Q3 FY2025 | −0.92 | −1.38 | −50.39% | — |
| Series | 1W | 1M |
|---|---|---|
| QURE | −7.6% | +0.1% |
| Peers | +1.5% | +5.2% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 13 | 25 |
